Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 74

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 74
---
 willing to pay in the future for
shares of our Common Stock, thereby depressing the market price of our Common Stock. In addition, because our Board is responsible for
appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or
remove our current management by making it more difficult for stockholders to replace members of our Board. Among other things, these
provisions:

| ● | allow the authorized number of our directors to be changed only by resolution of our Board;                                                         |
| ● | establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board;          |
| ● | require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; |
| ● | prohibit our stockholders from calling a special meeting of our stockholders;                                                                       |
| ● | provide that the Board is expressly authorized                                                                                                      
 to adopt, amend, alter, or repeal our bylaws;                                                                                                       |

| 33 |

| ● | establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and                                                                                                                                             |
| ● | authorize our Board to issue Preferred Stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called “poison pill,” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board. |

Any provision in our Charter or A&R Bylaws that
has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for
their shares of our Common Stock and could also affect the price that some investors are willing to pay for our Common Stock.

Certain provisions of the DGCL may have anti-takeover effects that could delay, defer, or discourage another party from acquiring control of the Company, prevent changes in our Board or management, and make certain transactions more challenging that stockholders might otherwise believe to be in their best interests.

We are subject to the provisions of Section 203 of
the DGCL, which generally prohibits us from engaging in a “business combination,” meaning a merger, asset sale, or other transaction
resulting in a stockholder’s financial benefit, with an “interested stockholder” for a three-year period following the
time that such stockholder becomes an interested stock